©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
An insight into the diagnosis and pathogenesis of hepatitis C virus infection
Mohammad Irshad, Clinical Biochemistry Division, Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi-110029, India
Dhananjay Singh Mankotia, Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi-110029, India
Khushboo Irshad, Department of Biochemistry, All India Institute of Medical Sciences, New Delhi-110029, India
Author contributions: Mankotia DS and Irshad K collected the information from published literature and categorized it under different sub-heads; Irshad M edited the manuscript and corrected/modified the language.
Correspondence to: Mohammad Irshad, Professor, Clinical Biochemistry Division, Department of Laboratory Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029, India. email@example.com
Telephone: +91-11-26594981 Fax: +91-11-26588663
Received: August 26, 2013
Revised: September 11, 2013
Accepted: October 13, 2013
Published online: November 28, 2013
Hepatitis C virus (HCV) was first characterized by Choo et al and Kuo et al in 1989. It was soon identified as the main causative agent of the disease previously known as post transfusion non-A, non-B hepatitis virus infection. HCV has been found to be an important cause of liver disease and remains a major public health problem worldwide. According to the World Health Organization, nearly 3% of the world population has been infected with HCV. Therefore, more than 170 million people are chronic carriers of HCV and at high risk of developing liver cirrhosis and/or hepatocellular carcinoma (HCC). Three to 4% of chronically infected individuals develop fatal HCC. Currently, HCC caused by HCV infection is considered an indication for liver transplantation[3-5].
HCV was the leading cause of post-transfusion and community-acquired non-A, non-B hepatitis until characterization of the virus in 1989 and the introduction of blood screening in 1990. The initiation of blood screening for HCV has markedly reduced its incidence. However, it still remains a significant problem in intravenous drug abusers. HCV infection is the most common cause of liver transplantation in adults. HCV and HIV-1 frequently co-infect humans and it has been estimated that as many as 18% of HIV-infected persons are also infected with HCV.
HCV is an enveloped RNA virus and belongs to the genus Hepacivirus of the family Flaviviridae. The HCV genome consists of 9.6-kb single-stranded RNA of positive polarity and a single open reading frame of 9033-9099 nucleotides flanked by a conserved 5’ and 3’ noncoding region (NCR) at the ends. Its genome codes for a long polyprotein of approximately 3000 amino acids which is processed co-translationally and post-translationally to yield structural proteins (core, envelope E1, and E2) and non-structural (NS) proteins (NS1/p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B). The envelope proteins (E1 and E2) are the outer surface proteins of the viral particles and play important roles in virus entry into the host cell. NS5B is a variable region of the HCV genome and codes for an RNA-dependent RNA polymerase (RdRp).
RNA polymerase lacks proof reading activity and this may alter the detection, sensitivity to interferon anti-viral activity and pathogenicity of the virus (Figure 1).
Figure 1 Proteins encoded by the hepatitis C virus genome.
Genome organization of hepatitis C virus showing the structure of the viral genome, including the long open reading frame encoding structural and nonstructural proteins, and 5’ and 3’ non-coding regions (NCRs). [Source: Monica A et al. Expert Rev Mol Med 2003; 5].
Like several other viruses, the RNA virus has a high degree of heterogeneity that varies 30%-35% among different genotypes. Based on previous studies, six major genotypes and more than 120 subtypes of HCV have been characterized to date. These HCV genotypes have distinct geographic distributions, with genotype 1 and 2 frequently found worldwide. In India, genotype 3 is reported to be the most prevalent, followed by genotype 1[11,12]. Different HCV genotypes have important epidemiological implications. Despite nucleotide sequence divergence between genotypes, they remain quite similar in their transmission pattern, persistence and disease development. Although genetic variation is attributed to several factors, two major theories i.e., the Darwinian and Neutral evolution theories are thought to be the prominent theories in causing genetic diversity in HCV. The nucleotide sequence variability is distributed throughout the viral genome. Regions encoding envelope proteins (E1, E2) and NS-1 are the most variable, whereas the 5’ NCR is the most conserved region.
HCV patients show a poor response to antiviral therapy based on the combination of pegylated interferon (IFN)-α and ribavirin. Only 40%-50% of patients infected with HCV genotype-1 and 80% of those infected with genotype-2 or 3 achieve a sustained virological response (SVR) with this regimen. The recent use of direct acting anti-viral (DAA) molecules, which are active on HCV during treatment, has led to a substantial improvement in SVR rates in HCV genotype-1 infected patients. However, this may lead to the selection of resistant virus if DAA molecules are used alone. Moreover, there is a high relapse rate of HCV infection after discontinuation of therapy. Recently, host genetic factors including human leukocyte antigen (HLA) and cytokine genes have been implicated in HCV infection or persistence. Genetic polymorphism of cytokine genes including IFN-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-10, IL-20 and SNPs in the promoter region of osteopontin gene, have been found to be crucial in determining the therapeutic outcome of HCV infection. Therefore, every effort is being made to understand the pathogenesis of HCV infection to create a therapeutic model for an effective treatment against HCV. Although recent reports describe the development of in vitro replication systems leading to the production of infectious viral particles[18,19], there is currently no cell culture model suitable for synthesizing vaccines based on killed or attenuated virus. All efforts have been focused on sub-unit vaccines, composed of one or several antigens, either in the form of recombinant proteins, synthetic peptides or vectored vaccines. The earliest vaccine developed for HCV was that by the Chiron group. However, very little progress was noted in this direction in subsequent years.
This article reviews the major aspects of HCV infection including the diagnosis and pathogenesis of HCV infection. Both of these aspects have a strong association with therapy, thus, newer means of accurate diagnosis and a better understanding of HCV infection pathogenesis may allow the development of a therapeutic model. This article attempts to update readers regarding the information available on these two aspects to date.
DIAGNOSIS OF HCV INFECTION
During HCV infection, every attempt is made to diagnose and differentiate acute from chronic hepatitis C infection. Acute HCV infection is typically mild. It is often not diagnosed, and the infection may be recognized only when it becomes chronic. The diagnostic tests used, including the presence of anti-HCV antibodies in serum, cannot differentiate between acute and chronic HCV infection because anti-HCV IgM, used as marker of acute infection, is variable in acute infectious disease and is also detected at high rates in patients with chronic HCV infection[22,23]. The diagnostic procedures for hepatitis C virus infection used in laboratories are based on the detection of anti-HCV antibodies against recombinant HCV proteins using enzyme immunoassay (EIA) and chemiluminescence immunoassay. Non-structural and recombinant antigens are used in these assays. Four different generations of anti-HCV test kits have been developed to date. The first generation EIA detected antibodies against the nonstructural proteins (NS4) with recombinant antigen c100-3. Subsequently, the second generation assay was developed and this included antigens from the core region (c22-3), the NS3 region (c33c) and a part of c100-3 (5-1-1) from the NS4 region. The third-generation EIA included an additional antigen from the NS5 region and a reconfiguration of the core and NS3 antigens. However, all these anti-HCV assays had the disadvantages of giving high false positive results and a lack of sensitivity to detect antibodies during the window period. In addition, these antibody-based assays could not distinguish between acute, past and chronic infections. This was followed by the development of supplementary tests involving the recombinant immunoblot assay (RIBA) which was commercialized. This assay contained recombinant antigen (c33c, NS5) and synthetic peptides (5-1-1, c100 and c22). Similarly, a few other commercial assays, known as third generation immunoassays incorporated HCV antigens from the core region, E2 hypervariable region, NS3 region, NS4A, NS4B and NS5A region. All these recombinant immunoblot assays were used as supplementary tests to the anti-HCV assays. Similar to EIA, the RIBA had the disadvantages of difficulty in performance and a high percentage of indeterminate results. Therefore, these are no longer used in diagnostic laboratories. Recently, fourth generation anti-HCV assays incorporating additional nonstructural proteins are being used as screening tests. These kits for anti-HCV detection target different HCV antigens and detect more than five primary antibodies to ensure the specificity and sensitivity of the detection kit.
Anti-C22c and anti-C33c may be the first HCV antibodies to appear during the acute phase of the disease, which is defined by elevated alanine aminotransferase (ALT) levels and/or clinical symptoms. Anti-NS5 appears somewhat later, while anti-C100-3 is the last antibody to be detected in acute self-limited HCV infection. The diagnosis and differentiation of acute from chronic HCV infection poses another problem. Patients chronically infected with one HCV-genotype develop acute hepatitis on infection with another genotype. Multiple episodes of acute hepatitis were observed in polytransfused thalassemic children reinfected with different HCV genotypes[26,27]. Therefore, discrimination between acute and chronic infection in the same patient is sometimes very difficult. HCV RNA in the serum or liver appears to be the earliest detectable marker of acute HCV infection, preceding the appearance of anti-HCV by several weeks. HCV viremia may persist despite the normalization of serum ALT levels. Thus, the use of ALT levels in the diagnosis of HCV is not helpful. However, HCV RNA in serum usually lasts for fewer than 4 mo in patients with acute self-limited HCV infection. The average time from transfusion to sero-conversion is approximately 11 to 12 wk with EIA-1 (Enzyme immunoassay-1) and 7 to 8 wk with EIA-2 (Enzyme immunoassay-2). Now attempts are being made to develop EIA assays to differentiate HCV sub-types. Patients with post-transfusion chronic non-A, non-B hepatitis develop anti-HCV antibodies in the majority of cases. Anti-HCV antibodies are not neutralizing, especially with HCV envelope proteins E1 and E2. High levels of anti-C100-3 were correlated with high titers of circulating HCV in chimpanzees. Therefore, the development and persistence of diagnostic antibodies to HCV seem to reflect concomitant virus replication and consequently a high potential for infectivity.
HCV RNA is frequently detected in patients with chronic hepatitis C and in patients carrying anti-HCV antibodies. A study carried out in Hong Kong demonstrated that 83% of anti-HCV positive patients were viremic when HCV RNA was determined using polymerase chain reaction (PCR) with two different sets of primers for noncoding regions. Similarly, in another study, 98 of 100 patients with chronic non-A, non-B liver disease were positive for antibodies by EIA-2, but all 100 patients were positive for HCV RNA by PCR. With the currently available EIA systems, chronic HCV infection can readily be identified in most patients. Measurement of HCV RNA by PCR does not substantially increase the numbers of patients found to have chronic HCV infection. Following the introduction and wider use of real-time PCR, it is now easier to diagnose and monitor the progress of HCV viremia in a very short time period. In addition, the use of multiplex PCR by real time is another advancement in the detection of possible hepatitis viral co-infections in single attempt analysis.
Based on published information regarding various aspects of HCV infection including the currently available diagnostic assays and therapeutic regimens, the American Association for the Study of Liver Diseases and Centers for Disease Control and Prevention, United States have approved a document as “practice guidelines” for use in the diagnosis and treatment of HCV infection. This is an important document and describes details of the guidelines to be followed for laboratory diagnosis of acute/chronic HCV infection.
PATHOGENESIS OF HCV INFECTION
HCV is a non-cytopathic virus that enters the liver cell and undergoes replication simultaneously causing cell necrosis by several mechanisms including immune-mediated cytolysis in addition to various other phenomena such as hepatic steatosis, oxidative stress and insulin resistance. The proteins/peptides encoded by different sub-genomic regions of the HCV genome and their quasispecies influence the above mechanism, and thus, have a significant role in HCV pathogenesis and disease causation. A brief description of HCV pathogenesis in the light of these factors is given in the following section (Figure 2).
Figure 2 Regulation of hepatitis C virus pathogenesis by host immunity and metabolic factors.
HCV: Hepatitis C virus.
HCV is a blood-transmitted virus that reaches the liver via circulation. The entry of HCV isolates requires at least 4 host-derived factors including scavenger receptor class B type I, Occludin, Claudin-I (CLDNI) and CD81. In addition, CLDN6 and CLDN9 have been shown to substitute for CLDN1 as HCV entry factors in human non-liver cells. The CD81 molecule on host cell surfaces acts as a viral receptor, which binds with the viral particle and facilitates its entry in the liver cell[37,38]. CD81 is expressed on the surface of almost all nucleated cells and complexes with a variety of other cell-surface receptors such as CD19 and CD21 on B cells, and sends a costimulatory signal to the cells. The viral envelop protein, E2, binds to the major extracellular loop of CD8. HCV shows multi-site binding and can also bind to several other molecules such as the receptor for low-density lipoprotein, the dendritic cell (DC)-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN), and its liver counterpart[41,42]. E2 is the most variable viral protein, and therefore, its interactions with CD81 have been reported to be strain-specific. It has two hyper variable regions, HVR-1 and HVR-2 which undergo frequent mutations, possibly due to virus-neutralizing antibodies and HCV-specific cytolytic T lymphocytes (CTLs). HCV also has a high mutation rate due to the lack of proofreading ability of its RNA-dependent RNA polymerase. Therefore, HCV exists in several distinct, but closely related virus species within an infected individual. These species are called HCV quasispecies.
Innate immunity presents a first line defense for the control of HCV infection as it does for several other viral infections. During HCV infection, cells produce Type 1 IFN which prepares and induces the cells to resist infection, check viral replication, promote adaptive immunity and activate natural killer (NK) cells, DCs and Kupffer cells etc. Once inside the cell, the innate immunity vs HCV is triggered through host recognition of viral macromolecular motifs, known as pathogen-associated molecular patterns (PAMPs), as non-self by cellular pathogen recognition receptors. These receptors includes toll-like receptors (TLRs) and retinoic acid-inducible gene-I (RIG-I) like receptors (RLRs). RIG-I binds PAMP on HCV-RNA and activates interferon regulatory factor-3 (IRF-3) for expression of IFN-α/β and anti-viral/interferon stimulated genes (ISGs). The secreted IFN and cytokines then activate NKs, DCs and Kupffer cells etc. These cells also play a significant role in mounting T/B cell-based immunity. The PAMP region lies on the 3’ untranslated region (UTR) of HCV and induces RIG-1 signaling that results in a RIG-1 interaction with IFN-β promoter stimulator (IPS-1) which causes activation of IRF-3 and nuclear factor κB (NFκB).
HCV can effectively evade innate immunity resulting in persistent viral infection. This occurs because HCV has evolved to counteract the RIG-1 pathway and thus evade the immune challenge. This phenomenon is the reason for chronicity in the majority of HCV infected patients. For this, the non-structural proteins of HCV i.e., NS3 and NS4A form a complex which activates the NS protease domain to target cleavage of IPS-1. After cleavage, IPS-1 can no longer signal downstream to activate IRF-3 and NFκB and the infected cells no longer produce IFN-β or express ISGs.
NK cells, a major arm of innate immunity, play an important role in eradication of HCV. The liver is enriched in NK cells that are usually activated in an early phase of HCV infection. The activated NK cells recruit virus-specific T cells and induce antiviral immunity in the liver. They also eliminate virus-infected hepatocytes directly by cytolytic mechanisms and indirectly by secreting cytokines including IFN-γ and TNF-α. These cytokines induce an antiviral state in host cells. Surprisingly, HCV has evolved multiple strategies to counter the host’s NK cell response. It is interesting that activated NK cells contribute toward liver injury, while inactive or compromised NK cells permit the virus to continue invasion.
After entry and replication of the virus inside liver cells, the viral molecules are transported to the endoplasmic reticulum and associate with major histocompatibility complex (MHC) molecules, which are finally transported to the cell surface. These molecules on the cell surface are recognized by T cells for their immune action. The majority of CTLs are CD8+ and recognize antigens presented on MHC class I molecules. Approximately 10% of CTLs are CD4+ which recognize antigens presented on MHC II molecules. These CTLs eliminate cells infected with virus. However, HCV is reported to have evolved mechanisms to avoid recognition by CTLs. They either reduce the expression of MHC molecules or prevent the viral peptide from presentation at the cell surface. Thus, CTLs play a major role in viral eradication and immunopathogenesis of HCV infection.
In another pathway of the disease mechanism, the destruction of HCV-infected hepatocytes release HCV fragments that are taken up by myeloid DCs. These DCs migrate to the draining lymph nodes and express HCV antigens on HLA class II molecules. Subsequently, they increase expression of costimulatory molecules (CD80, CD86) which interact with and activate antigen-specific helper T (Th) cells. These activated Th cells promote the maturation of DCs and increase the expression of CD40 ligand and TNF-α. The mature DCs induce T-cell activation by overexpression of their surface molecules. They also enhance antigen presentation capacity via HLA-I and production of cytokines that stimulate T-cell activation. IL-12 has been shown to play an important role in stimulating IFN-γ production from activated T cells[54,55], and thus, induces development of the type 1 (Th1) immune response characteristic of CTL activation. The effector CTLs release perforin, granzyme, and TNF-α, or express Fas ligand, and initiate a direct attack on HCV-infected hepatocytes[56,57].
The hepatocytes infected with HCV and DCs produce Type I IFNs which suppress viral replication by inducing enzymes such as 2’-5’ oligoadenylate synthetase (OAS) and RNA-dependent protein kinase (PKR) in hepatocytes. The plasmacytoid DC recognizes HCV-related markers through TLR-7, which interacts with single-stranded RNA. The TLR-signaling up-regulates PDC-triggering receptor expressed on myeloid cells (PDC-TREM) which induce further production of IFN-α. Activated OAS destroys viral RNAs, whereas PKR inhibits forming polysomes of viral mRNA. When HCV-specific CTL responses are not strong enough to eradicate the virus this leads to persistent infection.
Successful clearance of HCV during acute HCV infection depends on the rise, vigor and persistence of the Th1 immune response[62,63]. Patients who developed a strong Th1 response showed efficient viral clearance and a self-limited disease course. In contrast, those who lacked IL-12 and IFN-γ production invariably developed chronic persistence of the virus. The majority of patients fail to control the infection and develop a chronic infection with a variable degree of hepatitis and viremia[64,65]. Experimental studies have also demonstrated that HCV components induce an antigen processing mechanism and IFN-stimulated genes in infected livers[66-68]. Impaired function of DCs, as antigen-presenting cells in inducing immunity, may be responsible for the impaired immune responses. Various studies have reported that viral proteins including HCV core, E1, and NS3 inhibit DC maturation[69,70]. HCV infects DCs through the binding of HCV E2 protein and thereby suppress DC function in promoting an antiviral effect[41,71].
CTLs activated by viral proteins, not only kill virus-infected cells, but also contribute to virus control through a noncytolytic mechanism by secreting cytokines, e.g., IFN-γ, IFN-α/β and TNF-α. These cytokines induce an antiviral state in host cells. This also renders uninfected cells resistant to infection and prevents viral replication. The progression of the majority of infected persons to chronic infection suggests inability of the antiviral immunity to contain this infection. There may be several reasons for this failure, including the emergence of escape variants as a result of a high rate of virus mutations, decreased production of antiviral cytokines or “stunning” of HCV-specific CTLs, a compromised cytolytic potential of the CTLs and antagonistic peptides.
It is important to note here that the HCV genome in a single host is a dynamic population of different, but closely related genomes, designated quasispecies. The generation of quasispecies is usually ascribed to high variation in hyper variable region-1 (HVR-1) during viral replication. In acute resolving hepatitis, HVR-1 shows very little variation, as compared to that in chronic hepatitis. HVR-1 induces anti-HCV neutralizing antibodies[75,76] and HVR-1 specific CD4+ and CD8+ T cells[77,78]. Using the responding host cellular immune response differentially, HVR-1 favors viral escape[79,80]. HVR-1 variations result from the action of a continuous immune-driven positive selection[81,82]. Thus, HVR-1 complexity helps in the virus adaptive strategy to escape the immune onset. HCV clearance is associated with a vigorous HCV specific CD4+ and CD8+ T cell response in the acute phase of infection. In contrast, viral persistence is associated with a weak and dysfunctional virus specific T cell response[79-83]. T cell failure and HCV immune evasion have been explained in several reports[84-86].
Role of T regulatory cells in adaptive immunity
Recent studies have suggested a possible role for different regulatory T cell populations in HCV persistence. These studies showed a higher frequency of CD4+CD25+ regulatory T cells in the blood and CD4+FoxP3+ T cells in the liver of chronically HCV infected patients[87-89]. CD4+CD25+ regulatory T cells suppress HCV specific CD8+ T cell and CD4+ T cell proliferation as well as CD8+ T cell IFN-γ secretion[87,90-92]. After HCV antigen stimulation, Treg cells secrete IL-10 and transforming growth factor-β (TGF-β) which suppress virus specific T cell responses[91-93]. CD4+CD25+ Treg cells obtained from chronically HCV infected patients demonstrated greater suppressive activity against HCV specific CD8+ T cells compared to Treg cells isolated from acute HCV infected patients. However, the suppressive effect observed in patients who successfully cleared the virus was still significant. Another study showed that the frequency of CD4+CD25+FoxP3+ Treg cells and their suppressive capacity against virus specific T cell responses were as high in HCV recovered chimpanzees as those in persistently HCV infected chimpanzees. This observation requires further in-depth studies to explore the actual suppressive effect of Treg cells during HCV infection. Induction of Treg cells by HCV antigens was first demonstrated by the response of CD4+ T cell to HCV core protein. HCV-specific IL-10 secreting T cells were detected in the blood of chronic HCV infected persons. Regulatory CD8+ T cells may play an important role in chronic HCV infection. HCV-specific CD8+CD25+FoxP3+ T cells from the blood of chronically infected patients suppress HCV-specific T cell responses via TGF-β secretion. The blockade of TGF-β markedly enhanced HCV specific IFN-γ secretion by CD4+ and CD8+ T cells.
Few other studies have shown that chronic HCV infection results in exhaustion or impairment of HCV-specific CD8+ T cells. During chronic HCV infection, CD8+ T cells fail to proliferate or secrete antiviral cytokines including IFN-γ. This phenomenon is promoted by a lack of CD4+ T cells and the expression of immunomodulatory cytokines such as IL-10. The major cause of HCV-specific CD8+ T cell impairment is ascribed to the expression of inhibitory receptors such as Programmed death-1, lymphocyte-activation gene-3 (a protein related to CD4), CTLA-4 (a member of the CD28 receptor family), T-cell immunoglobulin mucin-3 and 2B4 on HCV-specific CD8+ T cells in blood and liver. Expression of these inhibitory receptors is associated with low levels of CD127 expression and impaired proliferation and differentiation of T cells. Thus, different mechanisms contribute to the dysfunction of HCV-specific CD8+ T cells in chronic HCV infection.
In addition to cytotoxic T lymphocytes, humoral immune response against viral and cellular components during HCV infection is also present. Patients positive for HCV RNA and/or anti-HCV antibodies have type I anti-liver kidney microsome antibodies, which also recognize cytochrome P450 (CYP) 2D6. The patient’s liver is infiltrated with auto reactive mononuclear cells, which recognize CYP2D6. It is interesting that the viral core protein residues 178-187 bear sequence homology with human cytochrome P450 (CYP2A6 and CYP2A7) residues 8-17. Although HCV is a hepatotropic virus and infects hepatocytes, viral genome and its replicative intermediates are frequently present in peripheral blood mononuclear cells and lymphoid tissues of chronically infected persons. The viral glycoprotein E2 has been implicated in the oligoclonal expansion of several lymphoma cells. The most common rheumatic and cutaneomucous symptoms in HCV-infected patients include fatigue, arthralgia, paraestheisa, myalgia, pruritus, and the sicca syndrome.
ROLE OF VIRAL PROTEINS AND GENOTYPES
The role of structural and non-structural components of the HCV virion has been explained by variation in their interactions with metabolites affecting pathogenic pathways leading to liver damage. HCV-core protein has a prominent role in all these interactions as compared to envelope and non-structural proteins. Moreover, when the mechanism of this interaction was studied in relation to various HCV genotypes, it was observed that different genotypes behave differently to regulate all these pathogenic pathways.
The role of NS5A and E2 region was found be important. NS5A has a role in viral replication, inactivating PKR[101-104], blocking the apoptotic pathway, binding of growth factor receptor-bound protein 2[105,106] and induction of anti-inflammatory interleukin secretion[107,108]. Similarly, E2 protein inhibits PKR[109,110]. The region of NS5A which interacts with PKR, shows clustering of amino acid changes during IFN treatment and plays an important role in the evasion mechanism. Furthermore, this association varies with genotype and thus, alters their sensitivity to IFN treatment. NS5A remains under strong immune selection, has T- and B-cell epitopes and possibly, in combination with individuals’ HLA, selects immune cells to produce sensitivity/resistance to IFN therapy. The functional activity of NS5A towards immune selection is clearly governed by the HCV-genotypes and varies accordingly. The response of genotype 2 and 3 to IFN treatment may be due to individuals recognizing the NS5A protein immunologically.
Binding of HCV E2 protein to DCs induces their maturation. Several HCV viral proteins, including core, NS3, NS5A and NS5B proteins, have been shown to inhibit DC functions. Consequently, the functions of both CD4+ Th cells and CD8+ CTLs are impaired in chronic HCV patients. This has been suggested to be one of the mechanisms that HCV utilizes to weaken host immune responses and spread the infection. Indeed, many clinical studies have shown that in chronic HCV patients, not only the functions of DCs are impaired[113,114], the functions of both CD4+ and CD8+ T cells are also impaired. A similar inductive effect of E2 protein was also reported in other cell types, including T cells, B cells, hepatocytes and hepatic stellate cells.
The role of HCV genotypes in the progression of liver disease is one of the most controversial areas of HCV research. In patients with chronic HCV, infection with genotype-1b is reportedly associated with a more severe liver disease and a more aggressive course than the infection with other HCV genotypes. Similarly, it was found that HCV genotype-1b was significantly more prevalent among patients with liver cirrhosis and those with decompensated liver disease requiring liver transplantation than among those with chronic active hepatitis C[119-121]. Although this is indirect evidence, it suggests an association between HCV genotype-1b and the development of these complications. HCV genotype-1b is a marker for more severe HCV associated liver disease, because it reflects a longer time of infection than a mere aggressive form of hepatitis C.
METABOLIC CONDITIONS AFFECTING HCV PATHOGENESIS
In addition to immune mediated HCV pathogenesis, there are several other clinical and metabolic conditions that have a strong association with HCV pathogenesis. These include HCV-induced insulin resistance, oxidative stress and hepatic steatosis. The following is a brief description of the conditions affecting HCV pathogens:
HCV-induced insulin resistance
HCV infection influences overall metabolism leading to increased steatosis, fibrosis, inflammation, apoptosis and insulin resistance (IR)[122,123] during the course of the disease. The resulting IR shows a modulating impact on liver pathogenesis by HCV infection. IR increases the de novo lipogenesis i.e., fatty acid (FA) synthesis via overexpression and maturation of SREBP-1c. This in turn, increases the activities of lipogenic enzymes including Acetyl CoA carboxylase and FA synthase. At the same time, intermediates of triglyceride biosynthesis also activate inhibitors of insulin signaling. For example, activation of protein kinase C-E by phosphorylating insulin receptor substrate, and thus inhibiting phosphatidyl inositol-3,4,5-triphosphate, inhibits Akt translocation by ceramides etc.. HCV-core protein, either directly or via increased secretion of TNF-α, causes IR[127,128]. The HCV core can activate inhibitors of insulin signaling including mammalian target of rapamycin and suppressor of cytokine signaling (SOCS)-3 and C-Jun N-terminal kinase (JNK)[130,131]. The activation of JNK by HCV core may follow a direct or indirect proinflammatory cytokine-mediated mechanism.
HCV-associated oxidative stress
Oxidative stress is reported to be an important part of HCV-induced liver damage. Previous studies investigated the role of different molecular components of HCV structure in modulating oxidative stress during HCV infection. HCV-core protein present within the outer membrane of mitochondria induces oxidation of glutathione and promotes Ca2+ uptake into mitochondria. Clément et al explained the molecular mechanism and demonstrated that following glutathione oxidation, there is increased reactive oxygen species (ROS) production by mitochondrial electron transport complex I and III. The HCV non-structural protein, NS5A, promotes ROS production in the membrane of endoplasmic reticulum (ER) by activating the release of Ca2+ from ER, thereby inducing oxidative stress. NS3 protein induces ROS production by activation of NADPH oxidase. Increased ROS production and consequent oxidative stress is evident by the presence of markers of increased oxidative stress in the blood. Levels of 8-hydroxy deoxyguanosine and 4-hydroxy-2-nonenol are increased in HCV infection[132,133]. Similarly, few studies have shown reduced levels of glutathione during HCV infection. Another study showed that the serum level of thioredoxin, a marker of oxidative stress, was significantly reduced in HCV infection[134-136].
The presence of oxidative stress has been noted in different types of hepatitis including hepatitis B. However, there is a marked increase in oxidative stress (OS) in HCV infection. Several studies have shown that structural components of HCV induce effective OS. HCV-core and non-structural components, NS3 and NS5A proteins, directly induce OS[137-139]. Core protein is involved in OS generation via oxidation of mitochondrial glutathione and uptake of Ca2+ into mitochondria[139,140] thus, changing the permeability of its membrane. Electron transport complex I increases production of ROS and redistributes cytochrome from mitochondria to the cytosolic fraction. NS5A is associated with the ER membrane and activates signal transducer transcription and NFκB. These activations lead to inflammation, immune response and apoptosis. Similarly, NS3 triggers ROS by activating NADPH oxidase 2 in mononuclear and polymorphonuclear phagocytes which increase apoptosis of hepatocytes. All these reports conclude that the structural and non-structural components of HCV induce a significant increase in OS that results in liver damage during HCV infection.
HCV infection is reported to have a strong association with hepatic steatosis. There are several other factors also responsible for steatosis, which include alcohol consumption, obesity, and diabetes[145-147]. Studies on steatosis in relation to hepatotropic viruses demonstrated that HCV infection directly causes steatosis in some patients. Studies in experimental animals have shown that HCV-core protein promotes liver steatosis[149,150]. Furthermore, when steatosis was studied in relation to HCV-genotypes, it was noted that although steatosis is induced by all HCV-genotypes, it appears more prominent and frequent with HCV-genotype 3 infection[151-153]. In patients carrying genotype-3 infection, there was a good correlation between the level of steatosis and HCV replication[153,154] and the presence of HCV-core in the liver. In addition, steatosis resolves in patient with genotype-3 when treated successfully with anti-viral therapy as compared to those with non-genotype-3 who remain steatotic[155,156]. Steatosis reappears with relapse of infection. This clearly demonstrates that some HCV-genotypes have more steatogenic potential. Subsequent studies indicated that genotype-3 interferes with very low-density lipoprotein (VLDL) secretion. Core protein, which promotes lipid accumulation in hepatocytes[158,159], was more efficient from genotype-3 compared to core protein from genotype-1.
All these reports concluded that HCV causes steatosis in three different ways: (1) Impaired secretion of lipids from hepatocytes; (2) Increased de novo synthesis of free fatty acids (FFAs); and (3) Impaired FA degradation. The first aspect of HCV-induced steatosis was proposed due to the impaired secretion of VLDL. To substantiate this, reports from different studies demonstrated a decreased level of apolipoprotein B and cholesterol in chronic HCV infected patients[159,160]. These low levels pointed to HCV disturbing the assembly and secretion of VLDL from the liver. Another important aspect in this relationship was increased de novo synthesis of FFAs in the presence of HCV infection. In this context, it is suggested that HCV upregulated the sterol regulatory element binding protein-1c (SREBP-1c) signaling pathway with NS2 and NS4B proteins inducing SREBP at the transcriptional level[162,163]. SREBP was also induced by expression of HCV core protein. Studies in chimpanzees infected with HCV also demonstrated that HCV increased the activity of lipogenic enzymes such as ATP citrate lyase. HCV-core, in particular, activates and helps in cellular lipid synthesis, possibly via its binding with retinoid receptor.
HCV-induced steatosis is also due to impaired FA degradation by HCV. Expression of HCV-core protein is reported to reduce the expression of peroxisome proliferation activated receptor-α (PPARα), a nuclear receptor involved in FA degradation and down-regulation of mitochondria β-oxidation. Genotype-3 shows significant down-regulation of PPARα as compared to genotype-1[166,167]. HCV-core protein also down-regulates PPARα and therefore, is more effective when from genotype-3 as compared to genotype-1. The core protein from genotype-3 also down-regulated the PPARγ and up-regulated SOCS-7 in human hepatoma cells. These data clearly show that HCV-core protein may modulate the expression of various genes responsible for FA degradation via down-regulation of PPARs.
HCV infection, previously known as blood borne non-A, non-B infection, is a serious public health problem worldwide. The diagnosis of HCV is based on the detection of anti-HCV antibodies and/or viral nucleic acid in serum. Studies over the last few years have developed assays not only for the accurate serodiagnosis of infection, but also identification of HCV serotypes. The pathogenesis of HCV infection is quite complex and regulated by host immunity as well as several metabolic activities influencing liver function. Whereas both innate and adaptive immunity are involved in the pathogenic action of HCV, the cytotoxic lymphocytes are crucial in deciding the eradication or persistence of viral particles. Moreover, the persistence of HCV infection is also affected by viral proteins, HCV isotypes and liver metabolism. In order to understand HCV pathogenesis further investigations are needed.
We thank and appreciate the financial aid provided by ICMR, New Delhi, India to conduct this study. We are also thankful to Mrs. Suman Rawat for preparing this manuscript.
P- Reviewer: Wang Y S- Editor: Ma YJ L- Editor: Webster JR E- Editor: Zhang DN